/
Other
Double-Blind
18
Pipeline Programs↗
18
Active Trials↗
73
Companies Involved↗
Double-blind is an emerging landscape with 18 programs across 73 companies. The most active players are CSL Behring, Alphyn Biologics, Portal Therapeutics, Inc.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 21
Phase 34
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
16 of 17 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.
Analysis
Trial Status
241
clinical trials
Completed177 · 73%
Terminated22 · 9%
Unknown status15 · 6%
Not yet recruiting8 · 3%
Recruiting7 · 3%
Withdrawn7 · 3%
Other5 · 2%
Clinical Trials
Trial Activity
241 trials
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Recruiting·—·Phase 3·NCT06631287·550 enrolled
A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study
Active, not recruiting·WWalter Reed Army Institute of Research (WRAIR)·Phase 1·NCT04273776·90 enrolled
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules
Not yet recruiting·—·Phase 4·NCT06749470·480 enrolled
Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
Not yet recruiting·—·N/A·NCT06189885·184 enrolled
Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
Not yet recruiting·—·Phase 2/3·NCT07218575·60 enrolled
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)